AIM
ALXN

Advantage Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Advantage Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$74K Sell
759
-334
-31% -$37.6K 0.06% 276
2019
Q2 		$143K Buy
1,093
+18
+2% +$2.32K 0.11% 185
2019
Q1 		$145K Sell
1,075
-67
-6% -$8.33K 0.11% 184
2018
Q4 		$111K Sell
1,142
-73
-6% -$8.63K 0.08% 217
2018
Q3 		$169K Buy
1,215
+354
+41% +$44.4K 0.11% 156
2018
Q2 		$107K Hold
861
– – 0.08% 240
2018
Q1 		$96K Buy
861
+286
+50% +$34.2K 0.04% 261
2017
Q4 		$69K Hold
575
– – 0.02% 346
2017
Q3 		$81K Hold
575
– – 0.03% 306
2017
Q2 		$70K Sell
575
-100
-15% -$11.6K 0.02% 294
2017
Q1 		$82K Sell
675
-150
-18% -$19.3K 0.03% 254
2016
Q4 		$101K Hold
825
– – 0.04% 224
2016
Q3 		$101K Hold
825
– – 0.04% 217
2016
Q2 		$96K Hold
825
– – 0.05% 239
2016
Q1 		$115K Buy
825
+100
+14% +$14.7K 0.05% 199
2015
Q4 		$138K Hold
725
– – 0.07% 177
2015
Q3 		$113K Hold
725
– – 0.06% 196
2015
Q2 		$131K Hold
725
– – 0.06% 196
2015
Q1 		$126K Buy
725
+50
+7% +$9.05K 0.07% 193
2014
Q4 		$125K Buy
+675
New +$125K 0.09% 181

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Advantage Investment Management's ALXN Position: Q3 2019 in Review

Advantage Investment Management reduced its Alexion Pharmaceuticals (ALXN) stake by 31% in Q3 2019, selling an estimated $37.6K and leaving 759 shares worth $74K. The position accounts for 0.06% of the portfolio, ranked #276.

Advantage Investment Management first reported a position in ALXN in Q4 2014 and has held it in 20 quarters since. The position peaked at $169K in Q3 2018. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Advantage Investment Management held 759 shares of Alexion Pharmaceuticals worth $74K as of Q3 2019.
  • Advantage Investment Management sold 334 Alexion Pharmaceuticals shares in Q3 2019, an estimated $37.6K.
  • Alexion Pharmaceuticals made up 0.06% of Advantage Investment Management's portfolio in Q3 2019, its #276 holding.
  • Advantage Investment Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
  • Advantage Investment Management's Alexion Pharmaceuticals position peaked at $169K in Q3 2018.
  • 647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.